[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627417":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":25,"studyPopulation":26,"armGroups":21,"interventions":27,"overallOfficials":21,"centralContacts":39,"locations":45,"responsibleParty":61,"collaborators":21,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":21,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":21,"maxAge":21,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":21,"briefSummary":78,"conditions":79,"keywords":86,"overallStatus":90,"whyStopped":21,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Caja Costarricense de Seguro Social","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":21},[9,13,15,18],{"measure":10,"description":11,"timeFrame":12},"Change in atopic dermatitis severity over time","Measured using validated clinical severity scales EASI (Eczema Area and Severity Index)","5 years",{"measure":10,"description":14,"timeFrame":12},"Measured using the validated clinical severity scale SCORAD (SCORing Atopic Dermatitis) from baseline through follow-up visits during routine care.",{"measure":16,"description":17,"timeFrame":12},"Treatment patterns in moderate-to-severe atopic dermatitis","Type and duration of systemic or advanced therapies prescribed in real-world practice during the observation period.",{"measure":19,"description":20,"timeFrame":12},"Patient-reported quality of life","Change in Dermatology Life Quality Index (DLQI) scores over time during treatment.",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","PROSPECTIVE","This is a national, multicenter, observational registry of patients with atopic dermatitis treated in dermatology referral centers in Costa Rica. The registry aims to document demographic characteristics, disease history, severity, comorbidities, treatment patterns, and longitudinal outcomes in patients receiving systemic immunosuppressants, biologic agents, or other advanced therapies in routine clinical practice.\n\nData will be collected prospectively and retrospectively from medical records and routine clinical assessments, including validated severity indices (e.g., EASI, SCORAD, DLQI), treatment exposure, adverse events, and therapeutic response over time. The registry will allow evaluation of real-world effectiveness, safety, and treatment persistence, as well as characterization of moderate-to-severe atopic dermatitis in the Costa Rican population.\n\nThis registry does not modify clinical management; all treatments are prescribed according to physician judgment and standard care.","The study population includes pediatric and adult patients with moderate-to-severe atopic dermatitis treated in dermatology referral centers in Costa Rica who require systemic immunomodulatory or biologic therapy. These patients represent individuals with more severe or refractory disease seen in specialized care settings, often with significant disease burden, chronic course, and impact on quality of life. The registry captures real-world clinical practice across participating centers and reflects the national population receiving advanced atopic dermatitis therapies.",[28,32,34,36],{"type":29,"name":30,"description":31,"armGroupLabels":21,"otherNames":21},"DRUG","Abrocitinib","This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.",{"type":29,"name":33,"description":31,"armGroupLabels":21,"otherNames":21},"Upadacitinib",{"type":29,"name":35,"description":31,"armGroupLabels":21,"otherNames":21},"Baricitinib",{"type":37,"name":38,"description":31,"armGroupLabels":21,"otherNames":21},"BIOLOGICAL","Dupilumab",[40],{"name":41,"role":42,"phone":43,"phoneExt":21,"email":44},"Daniel E Barquero-Orias, Dermatologist","CONTACT","+506 83411026","debarque@ccss.sa.cr",[46],{"facility":47,"status":21,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Caja Costarricense del Seguro Social","San José","Provincia de San José","40901","Costa Rica","CR",{"type":54,"coordinates":55},"Point",[56,57],-84.08489,9.93388,{"lat":57,"lon":56},[60],{"name":41,"role":42,"phone":43,"phoneExt":21,"email":44},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Daniel Barquero Orias","Principal Investigator","100627417","atopic-dermatitis-treated-with-dupilumab-and-jak-inhibitors-in-costa-rica-100627417",false,"NCT07448363","Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria\n* Moderate-to-severe disease requiring systemic or advanced therapy\n* Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care\n* Evaluated in participating dermatology centers in Costa Rica\n* Available clinical records with baseline and follow-up information\n\nExclusion Criteria:\n\n* Lack of sufficient clinical data for severity or treatment assessment","ALL",{"count":74,"type":75},50,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?\n\nWhat treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?\n\nParticipants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.",[80,81,82,83,84,85],"Atopic Dermatitis","Atopic Dermatitis (AD)","Atopic Dermatitis (Eczema)","Atopic Dermatitis Patients","Atopic Dermatitis \u002F Eczema","Atopic Dermatitis, Unspecified",[87,38,30,33,88,89,35],"Registry","JAK-inhibitor","Atopic dermatitis","NOT_YET_RECRUITING","2026-04-02",{"date":93,"type":94},"2026-04-08","ACTUAL",{"date":96,"type":75},"2026-05",{"date":98,"type":75},"2031-05",{"name":5,"class":6},1]